If you are not happy with the results below please do another search
The current emergency use authorization (EUA) for Pfizer’s COVID-19 antiviral pill for high-risk adolescents will continue to remain in effect even if it receives full approval for use in some adults.
Organizations continue to recognize the value of the large volumes of data they have collected and their potential for improving the quality, safety, and continuity of care. To utilize the data effectively and appropriately realize these benefits, organizations must overcome the challenges associated with transforming the data for use in healthcare.
Q4 and full-year 2022 financial statements have revealed several companies slashing I-O pipelines. Here are just some of the factors at play.
The all-cash deal will be closed on or before March 31.
Danish drugmaker Novo Nordisk has been suspended from the Association of the British Pharmaceutical Industry for two years over what the ABPI on Thursday described as “serious breaches” of its code of practice.
The Alzheimer’s Association has deployed 1,000 people diagnosed with, or caring for someone with the disease, to meet with all 535 members of Congress across the United States and urge them to press Medicare for early access to a new class of drugs, beginning with lecanemab, that promise to slow the disease.
The 34th Annual Manny Awards recognize and celebrate the best in pharmaceutical and healthcare advertising. The awards gala will be held on April 20, 2023 at The Lighthouse, Pier 61, Chelsea Piers, New York City.
Current forms of fibrosis treatment may slow the course of the disease, at best, and are limited by safety concerns. However, Mediar is tackling fibrotic disease from a new angle.
Concentra’s offer comes three weeks after Jounce signed an all-stock merger deal with U.K.-based Redx Pharma, which the companies expect to complete by the second quarter of 2023. The resulting combined entity will retain Redx’s name and therapeutic focuses: fibrotic diseases and cancer.
Weeks after the FDA rejected Veru’s emergency use authorization bid for sabizabulin in COVID-19, the company announced plans to continue with late-stage development of the drug.
